ArticleNeoplasia (New York, N.Y.)2018
A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models.
Article in Neoplasia (New York, N.Y.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- A Preliminary Evaluation ofPharmaceutics · 2026Article
- The Pharmacological Activity of Non-Cannabinoid Phytochemicals inPlants (Basel, Switzerland) · 2026Review
- Unraveling the mechanism of mulberry leaf in alleviating hyperuricemia: key role of kaempferol by modulating AKT pathway and gut-kidney axis.Frontiers in microbiology · 2026Article
- The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens.Biomedicines · 2024Review
- Recent advances in flavonoid compounds for the treatment of prostate cancer.Molecular biology reports · 2024Review
- Article
- Therapeutic Importance of Kaempferol in the Treatment of Cancer through the Modulation of Cell Signalling Pathways.Molecules (Basel, Switzerland) · 2022Review
- The Protective Effect of Kaempferol Against Ischemia/Reperfusion Injury Through Activating SIRT3 to Inhibit Oxidative Stress.Brazilian journal of cardiovascular surgery · 2022Article
- Assessing the Mechanism of Action of "Fructus Ligustri Lucidi-Cuscutae Semen" in Prostate Cancer Treatment Using Network Pharmacology and Molecular Docking.Computational and mathematical methods in medicine · 2022Article
- Natural medicinal plant products as an immune-boosters: A possible role to lessen the impact of Covid-19.Case studies in chemical and environmental engineering · 2021Article
- Review
- Medicinal Plants as Sources of Active Molecules Against COVID-19.Frontiers in pharmacology · 2020Review
- Flavonoid Calycopterin Induces Apoptosis in Human Prostate Cancer CellsIranian journal of pharmaceutical research : IJPR · 2020Article
- Kaempferol: A Key Emphasis to Its Anticancer Potential.Molecules (Basel, Switzerland) · 2019Review
- The flavonoid quercetin decreases ACE2 and TMPRSS2 expression but not SARS-CoV-2 infection in cultured human lung cells.BioFactors (Oxford, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
Abstract
The high prevalence and long latency period of prostate cancer (PCa) provide a unique opportunity to control disease progression with dietary and nutraceutical approaches. We developed ProFine, a standardized composition of luteolin, quercetin, and kaempferol, and investigated its potential as a nutraceutical for PCa in preclinical models. The three ingredients of ProFine demonstrated synergistic in vitro cytotoxicity and effectively induced apoptosis in PCa cells. ProFine markedly affected the transcriptome of PCa cells, suppressed the expression of androgen receptor, and inhibited androgen-regulated genes. Oral administration of ProFine did not exhibit obvious toxicities in mice, and the three ingredients retained their individual pharmacokinetic and bioavailability profiles. Importantly, ProFine significantly retarded the growth of PCa xenografts in athymic nude mice and extended the survival of animals. This study provides preclinical evidence supporting the promise of ProFine as a safe, efficacious, and affordable intervention to control PCa progression and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.